Where:
Wyndham Boston Beacon Hill
5 Blossom Street
Boston, Massachusetts 02114
Admission:
$2699.00 - $5297.00
Categories:
Lectures & Conferences
Event website:
https://go.evvnt.com/3680743-3?pid=5248
With billion dollar acquisitions from BMS, Eli Lilly, Sanofi and AstraZeneca validating the commercial opportunity of radiopharmaceutical therapies, clinical programs are accelerating into Phase II/III at unprecedented speed. Yet the infrastructure required to sustain this growth is under immense strain. Isotope demand is outpacing global production; half lives leave no margin for error, and the gap between scientific ambition and operational capability is widening across the industry.
The question isn't whether the science works. It's whether you can deliver it.
The 4th TRP Supply Chain and Manufacturing Summit is the only industry meeting dedicated entirely to solving these challenges, bringing together the senior leaders responsible for turning pipelines into real, deliverable therapies.
In 2026, the stakes are higher than ever. As infrastructure struggles to keep pace and competition intensifies, the companies that solve supply, scale, and distribution first will define the future of radiopharmaceutical medicine.
Join the organizations leading the charge or risk being left behind.
URLs:
Tickets: https://go.evvnt.com/3680743-0?pid=5248
Brochure: https://go.evvnt.com/3680743-2?pid=5248
Prices:
Drug Developer Pricing - Full Access Pass: USD 4397.00,
Drug Developer Pricing - Conference Days Only: USD 3099.00,
Academic Pricing - Full Access Pass: USD 3797.00,
Academic Pricing - Conference Days Only: USD 2699.00,
Service Provider Pricing - Full Access Pass: USD 5297.00,
Service Provider Pricing - Conference Days Only: USD 3799.00
Speakers: Ken Baker, Head of Radioconjugate Manufacturing and Development, AstraZeneca, Thomas Birger Eden-Jensen, Vice President and Head of External Supply Management Radiopharmaceuticals, Bayer, Jarrod Longcor, Chief Operating Officer, Cellectar Biosciences, Maria Banach, Associate Director of Quality Assurance, Cellectar Biosciences, Christine Higgins, Executive Director of Quality, Cellectar Biosciences Inc., William Le, Senior Director of Clinical Operations, Clarity Pharmaceuticals, Anusha Ramachandran, Director of CMC Operations, Convergent Therapeutics, Inc, Kathleen Brady, Associate Director of Quality Assurance, Imaginab, Lotti Frauchiger, Head Of CMC, Molecular Partners AG, Daniel Teper, Founder and Chief Executive Officer, NAYA Therapeutics, Jason Hurt, Chief Medical Officer, NAYA Therapeutics, Kimberly Adkins, Senior Director of Manufacturing, Ratio Therapeutics, Anna Kulesza, CMC Program Lead, Telix Pharmaceuticals, Benjamin Blehm, Vice President of Business Strategy and Operations, TheraCea Pharma, Kara Weatherman, Clinical Professor of Pharmacy Practice and Director of Radiopharmaceutical Programs, Purdue University, Suzanne Lapi, Vice Chair of Research and Director of Radiochemistry Laboratory, The University of Alabama at Birmingham
Saturday, Jun 13, 2026 9:30a
The Newbury Hotel, Newbury Street entrance
Saturday, Jun 20, 2026 10:00a
St Francis of Assisi Church
Wednesday, Jun 17, 2026 6:00p
Boston Area Spanish Exchange (BASE)